Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib in Relapsed or Refractory DLBCL (CITADEL-202)
NCT02998476Phase 2Completed
- Sponsor
- Incyte
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of parsaclisib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Incyte. Primary endpoint: Objective Response Rate at 26 months. Started Mar 2017; status: completed.
02
Drugs
parsaclisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02998476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998476.